VEGFR1-3, FGFR1-4, RET, KIT, PDGFRα

These targets are a group of receptor tyrosine kinases including the vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptors (FGFR1-4), RET proto-oncogene, KIT (CD117), and platelet-derived growth factor receptor alpha (PDGFRα). They are crucial regulators of angiogenesis, cell proliferation, differentiation, and survival. Multi-targeted tyrosine kinase inhibitors such as lenvatinib, regorafenib, and sunitinib inhibit these receptors to suppress tumor angiogenesis and tumor growth. These targets play prominent roles in the pathogenesis of various cancers and proliferative diseases, making them key therapeutic targets, but with notable safety challenges due to the broad role of these kinases in normal physiologic processes

Other names

FLT1KDRFLK1FLT4c-KitCD117CD140a

Inhibition of tyrosine kinase activity; Blockade of growth factor-mediated signal transduction; Suppression of tumor angiogenesis; Inhibition of tumor cell proliferation and survival.